基于组织学的放射组学用于[18F]FDG PET识别胰腺癌组织异质性
本研究在29例胰腺导管腺癌患者中,利用MCT4免疫组化密度图提取病理组学特征,聚类识别出MCT4高表达/异质性亚组,并发现该亚组与特定[18F]FDG PET放射组学特征(较高SUVmean、SUVmax及二阶特征)相关;该7特征PET标签在71例独立队列中显示预后价值,可识别生存更差的患者。
要点
- MCT4高表达/异质性亚组与较高SUVmean、SUVmax及二阶放射组学特征相关。
- 基于7个放射组学特征的MCT4 PET标签在独立队列中识别生存更差的患者。
- 跨模态流程可基于免疫组化标志物筛选PET放射组学特征,非侵入性捕获瘤内标志物异质性。
核心结论
- 跨模态流程可基于特定生物学标志物的免疫组化分析开发PET扫描标签,本研究以胰腺癌瘤内MCT4表达水平筛选[18F]FDG PET放射组学特征。
- 放射组学评分有潜力非侵入性捕获瘤内标志物异质性,并识别预后不良的胰腺导管腺癌患者亚组。
研究设计与样本
- 使用29例同时具有肿瘤横截面和[18F]FDG PET/CT扫描的胰腺导管腺癌患者队列开发[18F]FDG PET放射组学标签。
- 通过MCT4免疫组化计算MCT4表达密度图并提取病理组学特征,聚类分析识别出2个MCT4表达模式不同的亚组。
- 从对应[18F]FDG PET扫描中识别与预设MCT4亚组相关的放射组学特征,并在71例胰腺癌患者独立队列中评估预后价值。
主要发现
- 复杂热图显示MCT4高表达/异质性亚组与较高的MCT4表达水平和局部变异相关。
- 该模式与特定[18F]FDG PET特征相关,表现为较高的SUVmean和SUVmax以及二阶放射组学特征,与局部变异相关。
- 基于MCT4的[18F]FDG PET标签包含7个放射组学特征,在71例独立胰腺癌患者队列中显示预后价值,识别出生存更差的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiomics features can reveal hidden patterns in a tumor but usually lack an underlying biologic rationale. In this work, we aimed to investigate whether there is a correlation between radiomics features extracted from [18F]FDG PET images and histologic expression patterns of a glycolytic marker, monocarboxylate transporter-4 (MCT4), in pancreatic cancer. Methods: A cohort of pancreatic ductal adenocarcinoma patients (n = 29) for whom both tumor cross sections and [18F]FDG PET/CT scans were available was used to develop an [18F]FDG PET radiomics signature. By using immunohistochemistry for MCT4, we computed density maps of MCT4 expression and extracted pathomics features. Cluster analysis identified 2 subgroups with distinct MCT4 expression patterns. From corresponding [18F]FDG PET scans, radiomics features that associate with the predefined MCT4 subgroups were identified. Results: Complex heat map visualization showed that the MCT4-high/heterogeneous subgroup was correlating with a higher MCT4 expression level and local variation. This pattern linked to a specific [18F]FDG PET signature, characterized by a higher SUVmean and SUVmax and second-order radiomics features, correlating with local variation. This MCT4-based [18F]FDG PET signature of 7 radiomics features demonstrated prognostic value in an independent cohort of pancreatic cancer patients (n = 71) and identified patients with worse survival. Conclusion: Our cross-modal pipeline allows the development of PET scan signatures based on immunohistochemical analysis of markers of a particular biologic feature, here demonstrated on pancreatic cancer using intratumoral MCT4 expression levels to select [18F]FDG PET radiomics features. This study demonstrated the potential of radiomics scores to noninvasively capture intratumoral marker heterogeneity and identify a subset of pancreatic ductal adenocarcinoma patients with a poor prognosis.
引用
- Smeets EMM, Trajkovic-Arsic M, Geijs D, et al. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. J Nucl Med. 2024. PMID: 38782455. doi:10.2967/jnumed.123.266262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。